Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Orgenesis Inc ORGS

Healthcare Biotechnology
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in... see more

Recent & Breaking News (NDAQ:ORGS)

Orgenesis Provides Year End Business Update

GlobeNewswire April 15, 2024

Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility

GlobeNewswire April 10, 2024

Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference

GlobeNewswire March 18, 2024

Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes

GlobeNewswire March 13, 2024

Orgenesis Inc. Announces $2.3 Million Private Placement

GlobeNewswire March 4, 2024

Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing

GlobeNewswire February 29, 2024

Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic

GlobeNewswire January 31, 2024

Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM

GlobeNewswire November 14, 2023

Orgenesis Provides Business Update for the Third Quarter of 2023

GlobeNewswire November 13, 2023

Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering

GlobeNewswire November 8, 2023

Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant Funding

GlobeNewswire November 2, 2023

Orgenesis Announces Withdrawal of Proposed Public Offering

GlobeNewswire October 30, 2023

Orgenesis Announces Proposed Underwritten Public Offering

GlobeNewswire October 30, 2023

CGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United States

GlobeNewswire September 21, 2023

Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support

GlobeNewswire September 6, 2023

Orgenesis Provides Business Update for Second Quarter of 2023

GlobeNewswire August 11, 2023

Orgenesis Schedules Second Quarter 2023 Business Update Conference Call

GlobeNewswire August 10, 2023

Orgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial Officer

GlobeNewswire July 13, 2023

Orgenesis Announces Name Change of Morgenesis Business Unit to Octomera

GlobeNewswire July 11, 2023

Orgenesis and University of California, Davis Sign Partnership Agreement for Rollout of Cell and Gene Therapy Mobile Processing Units and Labs Throughout California

GlobeNewswire June 7, 2023